From scientific complexity to market execution.

A practical, end-to-end guide to mRNA-LNP CMC—from templates, IVT mRNA, lipid raw materials, and scale-up to potency, stability, comparability, and current global regulatory expectations.

The bottleneck in In Vivo CAR T may be delivery rather than the CAR itself. This article examines ERTLNP, T-cell activation, mTOR signaling, CMC implications, and the emerging 2026 clinical landscape.

Executive Summary If you only have three minutes to read this article, here are five key takeaways: Aging is increasingly viewed as a biological process that can potentially be modified, rather than an inevitable consequence of time. The discovery of the Yamanaka Factors revolutionized modern biology by demonstrating that cell identity is reversible, leading to the development of induced pluripotent stem cells (iPSCs). Today, the most exciting direction in aging research is P

Executive Summary Pfizer has introduced a new platform called USTAT (Unified Sequential Template Amplification and Transcription). The platform uses Rolling Circle Amplification (RCA) to establish an mRNA manufacturing process that does not rely on traditional plasmid DNA. The time from DNA template generation to mRNA production can potentially be reduced to approximately two days. RNA quality approaches that of conventional plasmid DNA-based manufacturing, although challenge